Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

Also called NCT01951001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01951001
Other papers using this trial's data
  • Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial Thrombosis and haemostasis, 2021-10 DOI, PubMed 33401330

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01951001. Randomized; no masking; primary purpose treatment. Start 2013-07 (actual); primary completion 2015-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome
Condition
Acute Coronary Syndrome
Condition
Platelet Thrombus
Condition
Bleeding
Intervention (Drug)
Prasugrel
Lead sponsor
Gyeongsang National University Hospital (class: other)

Record details

Record id
cardio:ct-nct01951001
Content hash
e05d38f9a466a08aea82287de85f33e0009f2084d23099e81fdd62be1b7f24be